Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10229790

Executive function in schizophrenia.

D I Velligan·C C Bow-Thomas
View original source ↗Export metadata ↓

Abstract

Many domains of executive function are impaired in patients with schizophrenia including forward planning, concept formation, initiation, self-monitoring, and the ability to direct attention and memory. These impairments are noticeable against a background of generalized cognitive deficits, and many affect 40% to 95% of individuals with this disorder. Specific executive deficits appear to be related to specific symptom clusters and are linked to structural and functional brain abnormalities. Executive impairment predicts multiple domains of functional outcome in schizophrenia patients. Atypical antipsychotic agents and cognitive rehabilitation may be promising new approaches for the treatment of cognitive and functional impairment in schizophrenia.

Explore related subjects

Antipsychotic AgentsCognitionCognition DisordersFollow-Up StudiesFrontal LobeHumansNeuropsychological TestsPrefrontal CortexRecurrenceSchizophreniaTime FactorsJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D I Velligan, C C Bow-Thomas. 1999. Executive function in schizophrenia.. https://doi.org/10.1053/scnp00400024

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.

Tardive dyskinesia (TD) is characterized by involuntary movements predominantly in the orofacial region and develops in approximately 20% of patients during long-term treatment with typical antipsychotics. The high prevalence of TD and its disabling and potentially irreversible clinical course is an important shortcoming for treatment with typical antipsychotics. The studies presented in this article evaluate the role of single nucleotide polymorphisms in dopamine D3 receptor (DRD3) and CYP1A2 genes for propensity to develop TD in patients with schizophrenia. In theory, a combined pharmacogenetic analysis of pharmacokinetic and pharmacodynamic targets for antipsychotics should improve our ability to identify subpopulations that differ in drug safety profile. This information may in turn contribute to the design of more efficient clinical trials and thus expedite the development and regulatory approval of newer antipsychotic compounds.

Antipsychotic Agents↗
PubMed2001

Statistical analysis of repeated measurements with informative censoring times.

Incomplete repeated measurement data often arise in medical studies. A problem that has recently drawn much attention in the literature in this situation is that the incompleteness or missingness is informative or related to the underlying variable of interest. In this paper we propose a non-parametric global test for treatment comparison in the presence of informative incompleteness. A semi-parametric regression model is also presented for assessing conditional treatment effects given the drop-out patterns, adopting the idea similar to that behind the pattern-mixture modelling approach and discussed in Shih and Quan. The proposed methods can be easily implemented and are conceptually simple and similar too, but can be applied to more general cases than those given in Yao et al. They are evaluated by numerical studies and applied to data from a clinical trial of adult schizophrenics.

Antipsychotic Agents↗